metastatic/advanced hepatocellular cancer (mHCC) | |
mHCC - 2nd line (L2) | |
pembrolizumab alone | KEYNOTE-240 KEYNOTE-394 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -